Johnson & Johnson is investing more than $2 billion to build a state-of-the-art biologics manufacturing facility in Wilson, NC. The new facility will expand production of the company’s portfolio and pipeline of biologics in support of J&J’s aim to advance more than 70 therapy and product expansion filings and launches by the end of the decade.
 
The new facility will expand production of biologics in areas including oncology, immunology, and neuroscience, with the latest technology focused on enabling efficient manufacturing operations. When fully operational, the site will employ approximately 420 full-time, highly skilled employees. Construction is anticipated to begin 1H25.
 
“A strong, global supply chain is crucial, and we purposefully invest to ensure our transformational medicines reliably and efficiently reach patients around the world,” said Dapo Ajayi, Vice President, Innovative Medicine Supply Chain, Johnson & Johnson. “We are investing in capacity and new technologies to enhance our industry leading capabilities and ensure a resilient supply chain for the future. North Carolina is an important hub for biopharmaceutical manufacturing and talent, and we are pleased to join this thriving life sciences ecosystem and become part of the Wilson community.”